Navigating the Evolving Regulation and Commercialization of Stem Cell Research

more+
less-

Interested parties that can successfully navigate the evolving regulation of stem cell research stand to gain significant scientific and commercial advantage.  Given that in the fall of 2011 the Court of Justice of the European Union issued a highly anticipated ruling regarding the patentability of human embryonic stem cells (hESCs) and many await the outcome to an appeal challenging the U.S. National Institutes of Health’s ability to fund hESC research, interested parties are encouraged to conduct a thorough assessment of their intellectual property portfolios and evaluate their current funding sources.